Imperative Care Appoints Henrietta Fore and Stacy Enxing Seng to Board of Directors

Respected leaders bring deep industry expertise and diverse perspectives to further enable company’s substantial growth CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the appointment of Henrietta Fore and Stacy Enxing Seng to the company’s Board of Directors, effective immediately. “The addition of Henrietta and Stacy to Imperative Care’s Board of Directors will prove invaluable as … [Read more…]

Cetya Therapeutics Welcomes Dr. Anthony Wutoh to its Board of Directors

Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell disease FORT COLLINS, Colo.–(BUSINESS WIRE)–Cetya Therapeutics, Inc. today announced the addition of Dr. Anthony Wutoh, Provost and Chief Academic Officer of Howard University, to its Board of Directors. Dr. Wutoh received a B.A. in Biochemistry … [Read more…]

Dalrada Financial Corporation Appoints Brian McGoff as President and Chief Operating Officer

SAN DIEGO–(BUSINESS WIRE)–$DFCO #BrianBonar–An innovator in clean energy, healthcare, and technology, Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada Financial Corporation,” “Dalrada”) announced the expansion of its executive leadership team naming Brian McGoff as President and Chief Operating Officer. Mr. McGoff’s achievements include implementing cost-effective strategies for executing domestic and international growth, building strong teams, and delivering … [Read more…]

U.S. Physical Therapy Announces Closing of New Credit Facility

Borrowing capacity increases by $175 million Base interest rate fixed on $150 million HOUSTON–(BUSINESS WIRE)–U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced the closing of a $325 million, five-year credit facility that includes a $150 million … [Read more…]

Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine

– Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease – – Presentation at the 12th International Symposium on Pneumococci and Pneumococcal Diseases – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of … [Read more…]

PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform

GC 2400 solution streamlines performance and delivers superior precision for high throughput environments WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the GC 2400™ Platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab … [Read more…]

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]

Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

New Drug Application filing anticipated based on positive data from interim analysis WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a statistically … [Read more…]

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

– Carbon is developing a novel parvovirus-based vector platform with demonstrated in-vivo tissue specificity, increased cargo capacity, and minimal natural neutralizing immunity; widens patient applicability and may enable gene therapy re-administration – Carbon’s lead candidate, CGT-001, targets lung tissue with demonstrated upper airway tissue tropism and repeatable dosing in gold-standard cystic fibrosis models – Financing … [Read more…]

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

MUNICH–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022. Frank H. Laukien, PhD, President and CEO of Bruker Corporation, commented: “Our differentiated high-value scientific instruments and … [Read more…]